Cargando…

Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease

OBJECTIVE: Several single-nucleotide polymorphisms have been identified to be disadvantageous or protective in regard to disease severity in patients with non-alcoholic fatty liver disease (NAFLD). However, it is unclear, whether including genetic risk factor(s) either alone or combined into risk st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paternostro, Rafael, Staufer, Katharina, Traussnigg, Stefan, Stättermayer, Albert-Friedrich, Halilbasic, Emina, Keritam, Omar, Meyer, Elias L., Stift, Judith, Wrba, Fritz, Sipos, Bence, Canbay, Ali, Schlattjan, Martin, Aigner, Elmar, Datz, Christian, Stickel, Felix, Schafmayer, Clemens, Hampe, Jochen, Buch, Stephan, Prager, Gerhard, Munda, Petra, Mandorfer, Mattias, Ferenci, Peter, Trauner, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382644/ https://www.ncbi.nlm.nih.gov/pubmed/34076851 http://dx.doi.org/10.1007/s12072-021-10200-y

Ejemplares similares

Ultra‐high‐field magnetic resonance spectroscopy in non‐alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non‐alcoholic steatohepatitis and advanced fibrosis
por: Traussnigg, Stefan, et al.
Publicado: (2017)

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Scheiner, Bernhard, et al.
Publicado: (2019)

HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilson’s Disease
por: Ferenci, Peter, et al.
Publicado: (2019)

Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
por: Traussnigg, Stefan, et al.
Publicado: (2020)

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection
por: Scheiner, Bernhard, et al.
Publicado: (2015)

Cystic Fibrosis Related Liver Disease—Another Black Box in Hepatology
por: Staufer, Katharina, et al.
Publicado: (2014)

AQP3 is regulated by PPARγ and JNK in hepatic stellate cells carrying PNPLA3 I148M
por: Tardelli, Matteo, et al.
Publicado: (2017)

Non‐invasive diagnosis of cirrhosis and long‐term disease monitoring by transient elastography in patients with Wilson disease
por: Paternostro, Rafael, et al.
Publicado: (2020)

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Mandorfer, M., et al.
Publicado: (2018)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
por: Burghart, Lukas, et al.
Publicado: (2021)

The rs738409 G Allele in PNPLA3 Is Associated With a Reduced Risk of COVID-19 Mortality and Hospitalization
por: Innes, Hamish, et al.
Publicado: (2021)

Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
por: Halilbasic, Emina, et al.
Publicado: (2013)

Bile acid transporters and regulatory nuclear receptors in the liver and beyond
por: Halilbasic, Emina, et al.
Publicado: (2013)

Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency
por: Luger, Maria, et al.
Publicado: (2016)

Pathophysiology and Management of Alcoholic Liver Disease: Update 2016
por: Stickel, Felix, et al.
Publicado: (2017)

Erratum: Pathophysiology and Management of Alcoholic Liver Disease: Update 2016
por: Stickel, Felix, et al.
Publicado: (2017)

Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR
por: Semmler, Georg, et al.
Publicado: (2021)

Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2022)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center
por: Semmler, Georg, et al.
Publicado: (2021)

Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon‐Free Therapy
por: Mandorfer, Mattias, et al.
Publicado: (2019)

Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study
por: Jachs, Mathias, et al.
Publicado: (2022)

Pathogenesis of primary sclerosing cholangitis
por: Pollheimer, Marion J., et al.
Publicado: (2011)

Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients
por: De Benedittis, Carla, et al.
Publicado: (2020)

Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreatobiliary Cancer
por: Sunami, Yoshiaki, et al.
Publicado: (2021)

PNPLA3 expression and its impact on the liver: current perspectives
por: Bruschi, Francesca Virginia, et al.
Publicado: (2017)

The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study
por: Poetter-Lang, Sarah, et al.
Publicado: (2018)

Plasma Levels of K18 Fragments Do Not Correlate with Alcoholic Liver Fibrosis
por: Schlossberger, Viola, et al.
Publicado: (2019)

Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2022)

Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center
por: Jachs, Mathias, et al.
Publicado: (2023)

Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression
por: Jachs, Mathias, et al.
Publicado: (2023)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH
por: Bruschi, Francesca V., et al.
Publicado: (2020)

Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms
por: Bellan, Mattia, et al.
Publicado: (2019)

Significant Liver-Related Morbidity After Bariatric Surgery and Its Reversal—a Case Series
por: Eilenberg, Magdalena, et al.
Publicado: (2017)

Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver disease
por: Hartl, Lukas, et al.
Publicado: (2022)

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2r1t4pp72h85qaf4qhvhlaedbl